Newsroom

Industry News

27 Sep

IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation

RICHLAND, Wash., Sept. 27, 2016 ­/PRNewswire/ — IsoRay, Inc. (“IsoRay”) (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that on September 23, 2016, it entered into...

Read more

27 Sep

Actinium Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

NEW YORK, Sept. 27, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed...

Read more

27 Sep

MTBC Successfully Launches Its Client Loyalty Program

SOMERSET, NJ–(Marketwired – Sep 27, 2016) – MTBC ( NASDAQ : MTBC ), ( NASDAQ: MTBCP ), a leading provider of cloud-based healthcare IT and practice management solutions, launched a first of its kind Client Loyalty Program two weeks ago, in partnership with SEC-registered online brokerage and technology company,...

Read more

26 Sep

Ascent Solar Secures New Funding

THORNTON, CO–(Marketwired – Sep 26, 2016) – Ascent Solar Technologies, Inc. (OTCQB : ASTI ), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the Company’s EnerPlex™ series of consumer products, announced today that the Company has entered into a Securities Purchase Agreement (“Agreement”) with an...

Read more

26 Sep

Actinium Pharmaceuticals to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant

NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has sponsored and will participate in the upcoming Be The Match® Walk+Run being...

Read more

26 Sep

NABUFIT Provides Operational Update; Reaches Over 100,000 Downloads in Two Months

OREM, Utah, Sept. 26, 2016 (GLOBE NEWSWIRE) — NABUFIT Global ApS, the wholly owned Danish subsidiary of NABUFIT Global, Inc. (NBFT), developer of a ground breaking new training portal that enhances  your workout by providing expert advice from professional trainers,  health experts and international sports stars, today provided an...

Read more

26 Sep

Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

NEW YORK, NY and CLEVELAND, OH–(Marketwired – September 26, 2016) – Abeona Therapeutics Inc. (ABEO) Phase 1 clinical trial in five patients demonstrated EB-101 (gene corrected skin grafts) was well tolerated and demonstrated promising clinical efficacy in patients for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) Significant improvements...

Read more

23 Sep

BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration

TEL AVIV, Israel, September 23, 2016 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology...

Read more

Page 1 of 18312345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address